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SpirometryAbstract Background: Chronic obstructive pulmonary disease (COPD) is a very common lung
disease most often related to history of smoking. It becomes more prevalent with increasing age
but remains under-diagnosed and under-treated in the elderly population. Under diagnosis of
COPD is universal in elderly patients because of multiple pathology, difﬁculty with measurement
of lung function, under-reporting of symptoms and reduced perception of dyspnoea. However
the screening of the elderly (age >60 years) is not performed routinely even when they are symp-
tomatic.
Objective: The study was undertaken to screen elderly subjects with dyspnoea and/or reduced
exercise tolerance for COPD.
Study design: A cross sectional hospital based study.
Methods: A total of 1000 elderly subjects were screened for COPD using standard spirometry as
per GOLD guidelines. Diagnostic evaluation and classiﬁcation of patients as ‘‘no COPD’’, ‘‘new
COPD’’ and ‘‘known COPD’’ were done by panel of experts which included a Pulmonologist,
Cardiologist, General Physician and Physiotherapist. Subjects were categorized as mild, moderate,
severe and very severe COPD based on FEV1 (forced expiratory volume in 1st sec) values.rculosis.
568 V. Mahishale et al.Results: Of the total 1000 elderly participants screened, 596 (59.6%) were classiﬁed as having no
COPD, 228 (22.8%) with new COPD and 176 (17.6%) with known COPD. Among the total 228 of
new COPD patients 27 (11.8%), 176 (77.4%), 5 (2.1%) and 20 (8.7%) were having mild, moderate,
severe and very severe COPD respectively as per GOLD guidelines. Similarly of the total 176
subjects with known COPD, 9 (5.1%), 136 (77.3%), 0 (0%) and 31 (17.6%) were having mild, mod-
erate, severe and very severe COPD respectively.
Conclusion: An active screening for COPD in elderly subjects with dyspnoea or reduced exercise
tolerance leads to diagnoses of substantially more new patients with COPD.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a very com-
mon lung disease most often related to history of smoking. It
becomes more prevalent with increasing age but remains
under-diagnosed and under-treated in the elderly population
[1]. All the studies conducted agree in predicting that both
morbidity and mortality burden of COPD are rising globally.
COPD is a progressive, partially reversible airﬂow obstructive
condition and is a growing public health problem. By 2020,
COPD is projected to cause over 6 million deaths annually
worldwide. In its advanced stage, the disease causes severe dis-
abilities and poor quality of life [2–4]. It was predicted that
COPD will be the third leading cause of death worldwide by
2020 with Asian countries having three times the number of
patients than the rest of the world [5–8].
The diagnosis of COPD is based on evidence of pulmonary
obstruction, in combination with signs and symptoms sugges-
tive of COPD and with history of smoking [9].
Pathophysiologically, it is well established that COPD can be
partly considered as accelerated ageing of the lungs and thus
its prevalence increases with age [10]. There is also accelerated
decline in forced vital capacity (FVC) and forced expiratory
volume in 1 s (FEV1) with natural ageing [11]. Ageing is asso-
ciated with a progressive degeneration of the tissues, which has
a negative impact on the structure and functions of lung tissue.
Since the proportion of the world’s population aged >60 years
will double in the next four decades, this will be accompanied
by an increased incidence of chronic age-related diseases like
COPD that will place a huge burden on healthcare resources.
Chronic pulmonary diseases represent an important compo-
nent of the increasingly prevalent multiple chronic debilitating
diseases, which are a major cause of morbidity and mortality,
particularly in the elderly.
Screening subjects at risk, such as smokers, workers and
populations exposed to environmental pollution, with serial
measurements of FEV1 have been shown to identify COPD
at an early stage, with a diagnostic yield that is signiﬁcant even
in asymptomatic individuals [12]. Under diagnosis of COPD is
universal in elderly patients because of multiple pathology, dif-
ﬁculty with measurement of lung function, under-reporting of
symptoms and reduced perception of dyspnoea [13]. However
the screening of the elderly is not performed routinely even
when they are symptomatic. Hence we undertook the study
of screening symptomatic (dyspnoea and/or reduced exercise
tolerance) elderly population (Age >60 years) for COPD
using spirometry as per GOLD guidelines [2].Methodology
Source of data
Inpatient and outpatient departments of Pulmonary medicine,
Internal Medicine, Cardiology and Geriatric departments at a
tertiary care hospital.Population
The study population included elderly subjects aged 60 years
and above with dyspnoea and/or reduced exercise tolerance,
registered in tertiary care hospital.Study design
A cross sectional hospital based study.
Study period
Primary data were collected from Jan 2013 to August 2014.
Sample size
Total of 1000 elderly subjects (>60 years) were screened for
COPD using spirometry.
Inclusion criteria
(1) Both male and female subjects with dyspnoea and/or
reduced exercise tolerance
(2) Age >60 years.
Exclusion Criteria
1. History of chronic lung disease other than COPD.
2. Any congenital cardiac disease.
3. Systemic diseases which can cause dyspnoea and/or
reduced exercise tolerance.
4. Chronic thromboembolic diseases.
5. HIV infection.
6. Subjects who could not perform spirometry.
7. Severe anaemia.
Table 1 Demographic characteristics.
Characteristics No COPD New
COPD
Known
COPD
Subjects (n) 596 (59.6) 228 (22.8) 176 (17.6)
Age (years) 72 ± 5.6 74.5 ± 6.2 76 ± 6.5
Males 331 (55.5) 109 (47.8) 92 (52.3)
Current/ex-smokers 345 (57.9) 136 (59.26) 124 (70.1)
Pack years 3.4 (0–19) 16.5 (0–32) 35 (16.5–50)
Asthma 36 (6.1) 35 (15.3) 13 (7.3)
MRC dyspnoea score 2 (2–3) 3 (2–4) 3 (2–4)
Exercise intolerance 1 (0–3) 2 (1–3) 3 (1–3)
Wheeze 85 (14.2) 94 (41.2) 86 (48.9)
Cough 109 (18.3) 106 (46.5) 85 (48.2)
Pre-bronchodilator
FEV1 predicted
96.5 ± 15.8 70.8 ± 13.2 64.2 ± 17.2
Post-bronchodilator
FEV1 predicted
99.2 ± 16.2 75.6 ± 13.8 68.6 ± 16.9
Table 2 Comparison between new and known COPD with its
severity.
GOLD criteria NEW COPD
N(%)
Known COPD
N (%)
Mild 27 (11.8) 9 (5.1)
Moderate 176 (77.4) 136 (77.3)
Severe 5 (2.1) 0 (0)
Very severe 20 (8.7) 31 (17.6)
Screening for chronic obstructive pulmonary disease 569Screening procedure
All participants in the study underwent a screening strategy,
including history taking, physical examination, ECG,
pre- and post-bronchodilator spirometry, blood tests, and
echocardiography. History taking included a standardized
questionnaire on symptoms, medical history, smoking history
and current drug use. Physical examination was performed
by an experienced physician in a standardized manner.
Situations in which the patients are dyspnoeic were scored as
0 (never), 1 (only during strenuous exercise), 2 (walking fast
or uphill), 3 (walking with people of same age), 4 (walking
ﬂat), 5 (at rest). Reduced exercise tolerance scores ranging
from 0 to 4 based on responses to the questions ‘‘do you have
a reduced exercise tolerance as compared to others of the same
age?’’, ‘‘do you feel more tired than others of the same age?’’,
‘‘do you feel you need more recovery time after exercise than
others of the same age?’’ and ‘‘do you feel your heart is pound-
ing, or feel palpitations or feel agitated during activities such as
walking, gardening or housework?’’ were recorded.
Spirometric measurements were performed while patients were
in a clinically stable condition with a RMS Helios 401 spirome-
ter (Recorders and Medicare systems private limited,
MEDSPIROR, India). FVC and FEV1 were measured before
and 30 min after administration of ipratropium bromide by
inhalation. All measurements were performed in a spirometry
Laboratory at tertiary care hospital under supervision of
Pulmonologist.
Panel diagnosis
All participants were evaluated by a consensus panel that
decided after plenary discussion whether a diagnosis of
COPD was present, possible or absent. Panel was consisted
of Pulmonologist, Cardiologist, General Physician and
Physiotherapist. Diagnosis of COPD was conﬁrmed as per
the guidelines of The Global Initiative for Obstructive Lung
Disease (GOLD) programme which provides standard
diagnostic criteria, severity staging as well as recommendations
for prevention and management of COPD [2]. Characteristics
of the participants in the screening were tabulated against the
COPD status deﬁned as ‘‘no COPD’’, ‘‘new COPD’’ and
‘‘known COPD’’. Patients with the label ‘‘no COPD’’ did
not have a prior diagnosis of COPD and had no COPD
according to the panel. Patients with new COPD had no prior
diagnosis of COPD but received such a diagnosis by the panel.
The group ‘‘known COPD’’ were patients known with COPD
that was conﬁrmed by the panel [14].
Results
Of the 1000 elderly participants screened, 596 (59.6%) were
classiﬁed as having no COPD, 228 (22.8%) with new COPD
and 176 (17.6%) with known COPD (Table 1). Among the
total 228 of new COPD patients 27 (11.8%), 176 (77.4%), 5
(2.1%) and 20 (8.7%) were having mild, moderate, severe
and very severe COPD respectively as per GOLD guidelines.
Similarly of the total 176 subjects with known COPD, 9
(5.1%), 136 (77.3%), 0 (0%) and 31 (17.6%) were having mild,
moderate, severe and very severe COPD respectively (Table 2).Discussion
In our study, among elderly subjects with complaints of dysp-
noea or with exercise intolerance, newly diagnosed COPD was
detected in 22.8% of the patients and known COPD in 17.6%
of subjects. This is in agreement with study by Bertens et al.,
which established that with an active search for COPD in com-
munity-dwelling frail elderly subjects with dyspnoea or
reduced exercise tolerance, substantially more new patients
with COPD can be detected than with care as usual (spirome-
try in suspected cases) [14]. In another study by Mourik et al.
Community-dwelling frail persons aged >65 years underwent
a 2-step screening strategy. First, they received a questionnaire
inquiring about dyspnoea and exercise tolerance. Those with
exercise intolerance and/or dyspnoea were invited to visit their
primary care physician’s ofﬁce for a screening, including medi-
cal history taking, physical examination, blood tests, electro-
cardiography, spirometry, and echocardiography. The ﬁnal
diagnosis of every patient was determined by a panel consist-
ing of 3 physicians. In this study previously unrecognized
COPD was detected in 16.8% (95% conﬁdence interval,
13.4–20.9%). In total, 165 patients (43.9%) received a new
diagnosis of either heart failure, COPD, or both. The study
concluded that unrecognized chronic diseases like COPD
might be detected in community-dwelling frail elderly using a
near-home screening strategy that is simple to implement
[15]. Our study also included a panel of clinicians including
Physician, Pulmonologist, Cardiologist and Physiotherapist
and all the participants in the trial underwent vigilant
570 V. Mahishale et al.evaluation by the panel after which patients were established
to be new COPD, known COPD and no COPD.
Many authors argue that screening for COPD would only
result in the detection of cases with mild disease, which are
often not considered clinically relevant. Especially in elderly
patients, a decline in pulmonary function is a part of the natu-
ral ageing process and differentiating between a normal of an
abnormal decline becomes difﬁcult. In our study, the majority
of patients with newly detected COPD had mild-to-moderate
disease based on airﬂow limitation. Signiﬁcant number of sub-
jects could be classiﬁed as having ‘‘more complaints’’ accord-
ing to the updated GOLD criteria in newly detected cases. In
current study there was no difference between new and known
COPD groups as far as symptom scores, exercise intolerance
and duration and pack years of smoking were concerned
(Table 1). This screening however demonstrated that con-
siderable numbers of subjects remain undiagnosed even when
they were symptomatic. This does suggest that screening of
elderly subjects with shortness of breath results in the detection
of clinically relevant COPD.
It is relevant to note that in 2012, the world population
reached 7 billion [16]. This notable population growth is the
result of several factors: contributions from medical,
technological and public health advances resulting in the con-
trol and treatment of communicable diseases; the control of
pandemics; the end of large-scale wars; improvement in living
conditions; and the agricultural revolution [17]. Because of
these improvements, life expectancy has increased dramati-
cally. In 1950, life expectancy at birth was 65 years in the more
developed regions of the world and 42 years in the less devel-
oped regions of the world. Currently, life expectancy is
78 years in the developed world and 68 years in the developing
world. At the same time, there has been a decline in population
growth rate. Population growth rate peaked at 2.2% per year
in the 1960s compared with the current estimate of 1.1% per
year. It is estimated to decline further to 0.5% by 2050 [18].
The combination of decreasing population growth rate and
increased life expectancies has led to a change in the
demographics of the population with the strata of older
individuals growing faster than the younger individuals. The
United Nations Population Division reported that the global
share of older people (aged 60 years or over) increased from
8% in 1950 and 9% in 1990 to 12% in 2013, and will continue
to grow to an estimated 21% by 2050. By 2045–2050, life
expectancy is projected to reach 83 years in the more devel-
oped regions of the world and 75 years in the less developed
regions of the world [18]. There is another important
‘‘epidemiological transition’’, which is the movement from
communicable diseases towards noncommunicable diseases
(NCDs) thorough the world [19]. Both population growth
and ageing are increasing the number of deaths from NCDs.
NCDs are characterized by slow progression and long dura-
tion; therefore, the clinical manifestation and burden dispro-
portionally affects older adults. The most important chronic
diseases include ischaemic cardiovascular disease, cere-
brovascular disease, COPD, diabetes, cancer and depression.
Considering the change in the demographics of the world
population and epidemiological transitions, there is justiﬁca-
tion for identifying elderly subjects with previously undiag-
nosed COPD. This kind of screening provides a window of
opportunity to the clinicians for early diagnosis of COPD in
subjects at risk. This would beneﬁt patients because symptomsand quality of life would be improved, exacerbations and com-
plications would be limited, and survival would be enhanced.
Also development and progression of the disease would be pre-
vented by intervention (e.g. smoking cessation) or pharmaco-
logical treatment at the earliest.
The power of or study are:
(1) It focuses on a speciﬁc group of subjects at high risk of
COPD: those who are symptomatic (dyspnoea and/or
exercise intolerance) and elderly.
(2) The screening was based not only on spirometry but also
on a detailed individual assessment by a multidisciplin-
ary panel (Pulmonologist, a General Physician, a
Cardiologist and Physiotherapist) that took into
account clinical history, risk factors, physical examina-
tion, blood tests, ECG, echocardiography, and pre-
and post-bronchodilator spirometry.
(3) The screening of the elderly population complaining of
dyspnoea included careful assessment of heart failure
and other causes of dyspnoea.
Limitations
The study is limited by the fact that it is a single centric cross
section study and hence the outcomes of the trial cannot be
generalized. Further studies with involvement of different geo-
graphic populations should be carried out. Also the impact of
early initiation of treatment and the disease outcome may be
studied, even in patients with a newly established diagnosis.Conclusion
An active screening for COPD in elderly subjects with
dyspnoea or reduced exercise tolerance leads to diagnoses of
substantially more new patients with COPD. It is imperative
to screen all elderly subjects (aged >60 years) to avert progres-
sion of the disease, improvement in quality of life & reduction
in mortality.Conﬂict of interest
None.
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